Member Info for panman

Bought a few today on the offchance this new development (and the saying goodbye to Adam) brings about a change in fortunes.

Will likely have to be patient but thats ok.

atb to the holders,

Agreed. I came to the conclusion they could deal with poor reliability re the trains or a lower than wanted coal price but not both which unfortunately seems to be what they've been faced with.

Pretty sure they were saying in their vids that breakeven was around the $207-$210 mark but that was when they reached 50K tonnes/month.

Not sure what breakeven is before that level but presume from todays RNS they're not producing that yet.

Good to see them buy the rest of setcar, seem to have got it pretty cheap too.

All we need now is a few more contracts please for what seems quite a promising part of the business imho;.

They can't have made the sales imho as they stated in their half year report last year and their Oct letter to shareholders that the admin of the hospitals and their sales partners Bayer et al were awaiting the CPT code before they could purchase the IB suite of products.

The half year report they expected it 2nd half as they were expecting a jump in sales 2nd half then by Oct letter it was final decision on it by May this year then in the non RNS'd newletter in Jan they stated later this year to reapply???

FAB dumped a shedload of shares just before the Jan letter which looks well suss and I wouldn't be at all surprised if it was because they'd been given the nod that the permissions weren't in so no significant software sales this year.

Don't like to be mistrusting but it fits with what's happened just as well as the view they were given the nod on a placing.

As said by others TR1's are going to be interesting if they bother.

Re their CPT code forgot about the letter to shareholders. That can happen when its not RNS'd.

CPT code won't be reapplied for until end of this year so who knows what sales they're actually making if any at all?

Lifted from advfn BB post 1450...

"Since submitting our Current Procedure Terminology (CPT) code application to the American Medical Association in November, we have had multiple productive exchanges with the CPT Editorial Panel.

Based on their excellent feedback and guidance regarding our code change application, we decided to revise and resubmit the application later this year. Specifically, and as suggested, the revised application will incorporate additional feedback from content experts and specialty societies such as the American Society of Neuroradiology, the American College of Radiology, and others.

We will also focus on the post-processing component and forgo the acquisition of the data, which was determined to be covered under an existing CPT code."

We were told they were expecting a stepchange in their revenue in their half year report due to the fact so many hospitals were evaluating their software as below..

"More than 45 different hospitals and healthcare systems are at varying stages of evaluating our software, with more sites entering the sales pipeline. This step-change in pre-sales activity is approximately a seven-fold increase over previous periods and is due, in large part, to the traction gained from our platform partners including TeraRecon (Eureka) and Bayer (Calantic). These partners have the medical expertise and marketing reach to sell our technologies into large existing installed customer bases and have ample sales and marketing resources to win clients.

It is a relatively easy up-sell for IB's partners' sales teams to activate IB's technology on platforms already being used clinically. The number of sites evaluating our software continues to increase. Thus, we are optimistic about the revenue activity and anticipate a step-change starting in the 2nd half of 2023.

But it was all talk about evaluation and when their 13 Oct letter to shareholders came out they were already backtracking due to a lack of a CPT code. Apparently that was stopping hospital administrators from purchasing "IB products."

They're not expecting a final decision til May this year so presume sales will be stymied til then?

From their 13th Oct update..

"Finally, funding from current NIH grants continues and new funding opportunities are being explored. It is through these grant collaborations with top academic centers that result in the translation of ground-breaking treatments into routine clinical care. We have identified a large new grant opportunity that is specific to our core imaging technologies, and we are evaluating potential aims for a February submission."

maybe they failed so had to place unexpectedly? (trying to find a reason to be kind)

We don't know the PRD's been resubmitted. There's been no RNS on it so just an assumption til they update.

You'd think they could at least have updated on this but no too busy selling their shares ahead of the placing to bother.....

"Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), reports that it will modify and resubmit its application for Pediatric Rare Disease (PRD) Designation, in response to a letter from the FDA encouraging a resubmission for a narrower target population.

IB is actively working on the request with plans to resubmit by the end of next week."

Got enough myself but not a seller. Will wait til they've got a real marketcap for that. lol

Not the time to sell anyway imo. M2G sounds like its picking up traction in the US which could be massive for SNT and it also sounds like there'll be quite a bit of newsflow coming out re b.grn in the US over the next few months.

Exciting times for SNT just a shame the markets so dire at the mo.

Not sure what to make of the placing? £40K isn't much to worry about in any case just unsure on the size of the broker option?

Sounds like B.grns going ahead in the US. Wonder which city it is backing them?

Re the subscription..100M shares at 3.75p the rest at 10p?

Going to be fascinating to watch. No way around it a 100M placing at 3.75p is a biggie but its been known they'd hit the market for a while.

Will the 10p level hold or will it crater to placing levels? Lay your bets and take your chances imo.

Not looked for a while, a lot closer to my 8p target though and a board full of peed off pi's arguing with each other like schoolies.

Sudden expected news notwithstanding cash ready but still holding out on the buying seems best move for now.

atb

Was an interesting contract, would have been better if they could have given an indication of what its worth imo.

Market seems as unsure of its value to the co. as I am.

Avani seem to be playing quite fair what with the extra funds and offtake agreement, if anyone saves ben will likely be largely with a lot of their help imo.

Find this comment interesting will be watching for how they change the terms etc- wonder if it will become convertible if not do they mean a longer period for payback?

"Pending execution of any working capital facility agreement, Avani has advanced $1.25 million to support the Company's operating requirements. It is also anticipated that as part of agreeing the new working capital facility that there will be amendments made to certain terms of the $6.5 million loan facility put in place in July 2023 between Avani and the Company"

Adam resigning is a bit of a surprise. His bonus makes sense now though imo. Presuming he knew when he took it the co' would fold and wanted as much out of it as possible before it did so.

The other alternative is he really believed he deserved $850K as a bonus for delivering a $20M loss and that's just too ridiculous to believe.

Too many 100K sellers to gain any momentum though. Beginning to wonder what this stock has to do to gain enough market confidence to maintain a rise?

Just the investor meet cancelled? Get it now. Thought it was the gm and since we all vote online anyway didn't see it as an issue for them.

atb,